What's Happening?
Allergan Aesthetics, a subsidiary of AbbVie, has received approval from the U.S. Food and Drug Administration (FDA) for its product SKINVIVE by JUVÉDERM. This injectable is the first hyaluronic acid-based treatment approved to reduce horizontal neck lines,
commonly referred to as 'tech-neck.' The condition is often caused by the frequent downward head position associated with using electronic devices. SKINVIVE by JUVÉDERM, which was previously approved for improving cheek skin smoothness, now offers a minimally invasive option for neck wrinkle reduction. The treatment involves using an ultrafine needle or cannula and includes a local anesthetic to enhance patient comfort. Clinical trials showed significant improvement in neck lines for a majority of participants, with effects lasting up to six months. The product is expected to be commercially available later this year, following a mandatory training program for providers.
Why It's Important?
The FDA's approval of SKINVIVE by JUVÉDERM marks a significant advancement in aesthetic treatments, particularly for addressing the growing concern of 'tech-neck' among adults. This development highlights the increasing demand for non-invasive cosmetic procedures that cater to modern lifestyle-induced conditions. The approval not only expands Allergan Aesthetics' portfolio but also sets a precedent for future innovations in the aesthetics industry. The product's ability to improve neck appearance with minimal downtime could attract a wide range of consumers seeking effective yet convenient solutions. This could potentially lead to increased market competition and drive further research and development in aesthetic treatments.
What's Next?
Following the FDA approval, Allergan Aesthetics plans to roll out SKINVIVE by JUVÉDERM later this year. The company will implement a training program for healthcare providers to ensure safe and effective administration of the treatment. As the product becomes available, it is likely to attract attention from both consumers and competitors, potentially influencing trends in the aesthetics market. The success of this product could encourage other companies to develop similar treatments, further expanding the range of options available for addressing tech-related aesthetic concerns.
